A naukri.com initiative
Silicon
2w
282
Image Credit: Silicon
AstraZeneca In $5.3bn AI Drug Discovery Deal With China’s CSPC
- AstraZeneca has entered a $5.3 billion deal with China's CSPC Pharmaceutical to use AI technology for developing oral drugs.
- The deal involves an upfront payment of $110 million to CSPC for using AI-driven drug discovery to analyze molecules for clinical success.
- The collaboration aims to address chronic health conditions affecting over two billion people globally.
- AstraZeneca highlighted the significance of partnerships in enhancing therapeutic molecule discovery for future medicines.
- The companies will focus on preclinical candidates targeting diseases across various chronic indications, including immunological diseases.
- CSPC stands to receive up to $1.62 billion in development milestone payments and $3.6 billion in sales milestones along with royalties.
- AstraZeneca had previously licensed a preclinical cardiovascular drug from CSPC for $100 million upfront.
- AstraZeneca is expanding its presence in China with a strategic research and development center in Beijing, part of a $2.5 billion investment in the city.
- The company faced challenges in China when its former China head, Leon Wang, was detained in connection with an investigation on illegal drug importation.
Read Full Article
17 Likes
For uninterrupted reading, download the app